Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors. A Phase II Study to Identify Molecular Predictors for Hormone Responsiveness and/or Resistance.
This study will develop preliminary data regarding the efficacy and safety of exemestane in
the preoperative treatment of postmenopausal women with ER+ or PR+ tumors. This trial is
also designed to develop a predictive model to correlate expression of the known isoforms of
ER and progesterone receptor (PR) and the aromatase enzyme with response to estrogenic
deprivation using exemestane.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Descriptive analyses will be performed to characterize the variability in the estrogen deprivation levels.
Up to 6 months
Anthony Elias, M.D
University of Colorado, Denver
United States: Institutional Review Board
|University of Colorado Cancer Center||Denver, Colorado 80262|